NIH Study Suggests That 200 mg Is The Optimal Daily Dose of Vitamin C

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 5 No 5
Volume 5
Issue 5

BETHESDA, Md--Although only 10 mg/day of vitamin C is enough to prevent deficiency, the optimal daily intake is probably 200 mg, according to results of a new NIH-sponsored study. The current Recommended Dietary Allowance (RDA) is 60 mg.

BETHESDA, Md--Although only 10 mg/day of vitamin C is enough toprevent deficiency, the optimal daily intake is probably 200 mg,according to results of a new NIH-sponsored study. The currentRecommended Dietary Allowance (RDA) is 60 mg.

In this study, vitamin C was given in various amounts to sevenhealthy young male volunteers who lived in a hospital ward forthe duration of the study so that intake could be strictly controlled.The NIH researchers, led by Dr. Mark Levine, found that the 200mg level was best absorbed by the body; absorption levels fellas the dose was raised above 200 mg.

Daily doses higher than 400 mg offer no additional value, Dr.Levine said, since, at that level, a large amount of the doseis excreted from the body. The research also suggests that veryhigh doses could be dangerous: At 1,000 mg/day, the urine wasfound to contain oxalate, a breakdown product of the vitamin thatcould lead to kidney stone formation in some people.

Recent Videos
Future findings from a translational analysis of the OVATION-2 trial may corroborate prior clinical data with IMNN-001 in advanced ovarian cancer.
The dual high-affinity binding observed with ISB 2001 may avoid resistance mechanisms reported with other BCMA-targeted therapies.
The use of chemotherapy trended towards improved recurrence-free intervals in older patients with high-risk tumors as determined via the MammaPrint assay.
Use of a pharmacist-directed resource appears to improve provider confidence and adverse effect monitoring for patients undergoing infusion therapy.
Reshma L. Mahtani, DO, describes how updates from the DESTINY-Breast09, ASCENT-04, and VERITAC-2 trials may shift practices in the breast cancer field.
2 experts in this video
Related Content